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Abstract
Background: Vascular endothelial growth factors (VEGFs) are key regulators of endothelial cell function and
angiogenesis. We and others have previously demonstrated that VEGF-A stimulates AMP-activated protein kinase
(AMPK) in cultured endothelial cells. Furthermore, AMPK has been reported to regulate VEGF-mediated
angiogenesis. The role of AMPK in the function of VEGF-B remains undetermined, as does the role of AMPK in
VEGF-stimulated endothelial cell proliferation, a critical process in angiogenesis.
Methods: Human aortic endothelial cells (HAECs) were incubated with VEGF-A and VEGF-B prior to examination of
HAEC AMPK activity, proliferation, migration, fatty acid oxidation and fatty acid transport. The role of AMPK in the
functional effects of VEGF-A and/or VEGF-B was assessed after downregulation of AMPK activity with chemical
inhibitors or infection with adenoviruses expressing a dominant negative mutant AMPK.
Results: Incubation of HAECs with VEGF-B rapidly stimulated AMPK activity in a manner sensitive to an inhibitor of
Ca
2+/calmodulin-dependent kinase kinase (CaMKK), without increasing phosphorylation of endothelial NO synthase
(eNOS) phosphorylation at Ser1177. Downregulation of AMPK abrogated HAEC proliferation in response to VEGF-A
or VEGF-B. However, activation of AMPK by agents other than VEGF inhibited proliferation. Downregulation of
AMPK abrogated VEGF-A-stimulated HAEC migration, whereas infection with adenoviruses expressing constitutively
active mutant AMPK stimulated chemokinesis. Neither VEGF-A nor VEGF-B had any significant effect on HAEC fatty
acid oxidation, yet prolonged incubation with VEGF-A stimulated fatty acid uptake in an AMPK-dependent manner.
Inhibition of eNOS abrogated VEGF-mediated proliferation and migration, but was without effect on VEGF-
stimulated fatty acid transport, ERK or Akt phosphorylation.
Conclusions: These data suggest that VEGF-B stimulates AMPK by a CaMKK-dependent mechanism and
stimulation of AMPK activity is required for proliferation in response to either VEGF-A or VEGF-B and migration in
response to VEGF-A. AMPK activation alone was not sufficient, however, to stimulate proliferation in the absence of
VEGF. VEGF-stimulated NO synthesis is required for the stimulation of proliferation by VEGF-A or VEGF-B, yet this
may be independent of eNOS Ser1177 phosphorylation.
Background
Vascular endothelial growth factor (VEGF)-mediated
stimulation of endothelial cell proliferation and migra-
tion are key events in angiogenesis. Manipulation of
VEGF signalling is seen as a promising therapeutic tar-
get for a number of disorders in which angiogenesis is
inappropriate, yet the molecular mechanisms of action
of VEGF in the endothelium are incompletely under-
stood [1-3]. There are several members of the VEGF
family expressed in humans. VEGF-A is thought to be
the key VEGF family member that promotes angiogen-
esis, through the stimulation of endothelial cell prolif-
eration, migration and survival [2,4-6]. VEGF-B is
regarded as poorly angiogenic in most tissues except
heart [6], yet improves survival in endothelial cells [7],
such that its role in angiogenesis remains unclear.
Recent studies have, however, identified a role for
* Correspondence: ian.salt@glasgow.ac.uk
2Institute of Cardiovascular & Medical Sciences, College of Medicine,
Veterinary & Life Sciences, University of Glasgow, Glasgow UK
Full list of author information is available at the end of the article
Reihill et al. Vascular Cell 2011, 3:9
http://www.vascularcell.com/content/3/1/9 VASCULAR CELL
© 2011 Reihill et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.VEGF-B signalling in the regulation of fatty acid
uptake in endothelial cells [8].
VEGFs bind to three related receptor tyrosine kinases,
VEGF-R1, -R2 and -R3, with VEGF-R1 and VEGF-R2 lar-
gely restricted to endothelial cells [3]. VEGF-R2 binds
V E G F - A ,b u tn o tV E G F - B ,a n di sc o n s i d e r e dt ob et h e
principal mediator of VEGF-A-regulated endothelial cell
proliferation, angiogenesis and endothelial permeability
[2,4,5]. The function of VEGF-R1, which binds both
VEGF-A and VEGF-B, is less clear [3], but has been
reported to promote endothelial cell survival [9], stimulate
endothelial cell migration [10] and NO synthesis [11].
AMP-activated protein kinase (AMPK) is the down-
stream component of a protein kinase cascade that reg-
ulates cellular and whole body energy status [12].
Furthermore, it is now clear that AMPK is an important
regulator of endothelial function [13]. We have demon-
strated that VEGF-A stimulates AMPK activation, con-
tributing in part to NO synthesis in cultured human
aortic endothelial cells (HAECs) [14]. Furthermore,
infection with adenoviruses expressing a dominant nega-
tive AMPK mutant inhibited VEGF-A-stimulated migra-
tion and endothelial tube formation under conditions of
hypoxia in human umbilical vein endothelial cells
(HUVECs), and reduced in vivo angiogenesis [15]. In
addition, siRNA-mediated knockdown of AMPK has
been reported to impair VEGF-A-stimulated bovine aor-
tic endothelial cell (BAEC) migration and endothelial
tube formation [16].
Taken together, these data indicate that AMPK is
required for the angiogenic response to VEGF-A, yet
whether AMPK mediates VEGF-B signalling has not
been reported. Furthermore, although AMPK has been
reported to regulate VEGF-mediated migration [16], the
role of AMPK in endothelial cell proliferation, a key
process in angiogenesis, remains uncharacterised.
Finally, the role of AMPK in any VEGF-mediated altera-
tions in fatty acid metabolism has similarly not been
reported. In the current study, we examined the role of
AMPK in the functional consequences of VEGF-A and
VEGF-B signalling in HAECs, focussing on proliferation,
migration and fatty acid metabolism.
Methods
Materials
Cryopreserved HAECs and cell culture media were
obtained from PromoCell (Heidelberg, Germany).
V E G F - Bw a sf r o mR & Ds y s t e m s( A b i n g d o n ,O x f o r d -
shire, UK). A769662 was a generous gift from Prof. D.
G. Hardie (University of Dundee, Dundee, UK). Com-
pound C was obtained from Merck Chemicals Ltd.
(Nottingham, UK). L-carnitine, palmitic acid, fatty acid-
free bovine serum albumin, C1-BODIPY
®500/510C12,
Dowex 1X8-200 and VEGF165 (referred to as VEGF-A
in this study) were from Sigma (Poole, Dorset, UK).
[9,10(n)-
3H]palmitic acid was from GE Healthcare Life
Sciences (Little Chalfont, Buckinghamshire, UK). CellTi-
ter AQueous one solution cell proliferation assay solu-
tion was obtained from Promega (Southampton,
Hampshire, UK). All other reagents were from sources
described previously [14,17,18].
Cell culture
HAECs were grown in large vessel endothelial cell med-
ium and used for experiments between passages 3 and 6
as described previously [14,17,18].
Preparation of adenoviruses and infection of HAECs
Control adenoviruses (Ad.control) and adenoviruses
expressing dominant negative mutant AMPKa1( A d .
AMPK-DN) or constitutively active mutant AMPK (Ad.
AMPK-CA) were propagated and purified as described
previously [18]. HAECs were infected with 25 pfu/cell
adenovirus in complete medium and the cells cultured
for 48 h prior to experimentation.
Preparation of cell lysates, SDS-PAGE and
immunoblotting
Cells were incubated in Krebs Ringer Hepes (KRH) buf-
fer (119 mM NaCl, 4.75 mM KCl, 1.2 mM MgSO4,5
mM NaHCO3, 1.3 mM CaCl2, 20 mM Hepes-NaOH,
pH 7.4, 5 mM glucose) for 3 h prior to the addition of
test substances and further incubated for various dura-
tions at 37°C. The medium was removed; lysates (0.5
ml) prepared, resolved by SDS-PAGE and transferred to
nitrocellulose. Nitrocellulose membranes were probed
with the antibodies indicated as described previously
[14,17,18].
Immunoprecipitation and assay of AMPK
AMPK was immunoprecipitated from lysates and
assayed using the SAMS substrate peptide as described
previously [14,17]. Protein concentration was deter-
mined by the method of Bradford [19].
HAEC proliferation assay
HAECs were cultured in complete media until 50-60%
confluent in a 96-well plate and incubated in serum free
culture medium for 2 h. Media was removed and
replaced with basal endothelial cell culture medium sup-
plemented with 0.2% (v/v) foetal calf serum. Cells were
cultured for a further 20 h in the presence or absence of
VEGF and/or inhibitors. HAEC proliferation was deter-
mined using the CellTiter 96
® AQueous One Solution
Cell Proliferation solution according to the manufac-
turer’s instructions. In experiments where AMPK adeno-
virus was used HAEC were infected for 24 h prior to
serum starvation.
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Migration assays were performed in a modified Boyden
chamber using a 48-well chemotaxis chamber (Neurop-
robe). A PCTE membrane was coated with 10 μg/ml
type IV collagen in serum free medium supplemented
with 0.5% (w/v) bovine serum albumin (BSA) for 1 h.
The filter was placed over a bottom chamber containing
VEGF in serum free medium-BSA. HAECs (1 ×
10
6cells/ml) were suspended in serum free medium-BSA
and 50 μl added to each well in the upper chamber.
HAECs were infected with adenovirus for 24 h before
experimentation. The assembled chemotaxis chamber
was incubated for 5 h and non-migrated cells on the
upper surface of the filter were removed by scraping.
The filter was stained with crystal violet and migrated
cells quantified by counting the mean number of cells
from 3 different fields at 40× magnification, performed
in triplicate.
Fatty acid oxidation assay
Palmitate oxidation was measured on the basis of
3H2O production. In order to account for intracellular
fatty acid pools, HAECs cultured in 12 well plates until
90-95% confluent were pre-labelled with 2 μCi/ml
[
3H]-palmitic acid 24 h prior to the start of the experi-
ment [20]. HAEC were incubated with 500 μl of 110
μM[
3H]palmitic acid (8 μCi/ml), 50 μM carnitine, 0.5
mg/ml fatty acid-free BSA (FF-BSA) in Earle’s-Hepes
(116 mM NaCl, 5.3 mM KCl, 0.8 mM MgSO4,1 . 8m M
CaCl2,1m MN a H 2PO4, 20 mM Hepes-NaOH, pH 7.4)
in the presence or absence of AICAR or VEGF for 4 h
at 37°C. At the end of the incubation period
3H2Ow a s
separated from the unreacted substrate by the addition
of 30 μl of 10% (w/v) FF- BSA. TCA (72% (w/v), 50 μl)
w a st h e na d d e da n di n c u b a t e da t4 ° Cf o r1 0m i n
before centrifugation at 2000 × g for 10 min at 4°C.
The supernatant was removed, the pH adjusted to 7-9
using 1 M NaOH and transferred to a Dowex 1X8-200
ion exchange column. Columns were eluted with 2 ml
of deionised water and
3H2O assessed by liquid scintil-
lation counting.
Fatty acid uptake assay
Confluent HAECs were cultured in 12 well plates in
serum-free growth medium supplemented with 1% (v/v)
FF-BSA in the presence or absence of test substances
for 24 h before being washed with PBS containing 1%
(v/v) FF-BSA and incubated at 37°C for 3 min in PBS,
1% (v/v) FF-BSA, 110 μM[
3H]-palmitic acid (6 μCi/ml).
[
3H]-palmitic acid transport was terminated by sequen-
tial washing in ice-cold PBS. Cells were lysed in 1% (v/
v) Triton X-100 and cell-associated radioactivity
assessed by scintillation counting.
Statistics
Unless stated otherwise, results are expressed as the
mean ± S.E. Statistically significant differences were
determined using a 2-tailed Student’s t test, with p <
0.05 as significant.
Results
VEGF-B stimulates AMPK via CaMKK in HAECs
Incubation of HAECs for 5 minutes with 10 or 100 ng/
ml VEGF-B significantly stimulated AMPK activity, yet
the magnitude of this stimulation was less than that eli-
cited by 10 ng/ml VEGF-A (Figure 1A). VEGF-B also
significantly stimulated phosphorylation of the AMPK
substrate, acetyl CoA carboxylase (ACC) (Figure 1B
&1C), which reached a maximum after 2-5 min before
returning to basal levels of phosphorylation (Figure 1D).
Unlike VEGF-A, VEGF-B had no significant effect on
eNOS Ser1177 phosphorylation in HAECs (Figure 1B-
D ) .W eh a v ep r e v i o u s l yr e p o r t e dt h a tV E G F - As t i m u -
lates AMPK by a CaMKK-mediated mechanism [14].
We therefore determined whether the stimulation of
AMPK by VEGF-B was sensitive to the CaMKK inhibi-
tor, STO-609. Preincubation of HAECs with STO-609
completely inhibited VEGF-B and VEGF-A-stimulated
AMPK phosphorylation at Thr172, yet had no effect on
AMPK Thr172 phosphorylation stimulated by AICAR
(Figure 2A), which stimulates AMPK phosphorylation
by a CaMKK-independent mechanism [12-14,17]. Incu-
bation of HAECs with VEGF-B had no additional effect
on VEGF-A-stimulated AMPK Thr172 or ACC phos-
phorylation (Figure 2B).
VEGF-stimulated HAEC proliferation requires AMPK
activity
We next determined the role of AMPK in VEGF-stimu-
lated HAEC proliferation. Both VEGF-A and VEGF-B
significantly stimulated HAEC proliferation in cells cul-
tured in low serum (0.2% (v/v)) concentrations. Incuba-
tion with the AMPK inhibitor, compound C, or STO-
609 prevented the stimulation of proliferation in
response to either VEGF-A or VEGF-B. Furthermore,
incubation with the eNOS inhibitor, L-NAME also com-
pletely abrogated VEGF-A and VEGF-B-stimulated
HAEC proliferation (Figure 3A). Co-incubation of
HAECs with VEGF-A and VEGF-B elicited no signifi-
cant increase in HAEC proliferation when compared to
stimulation with either VEGF isoform alone (Figure 3B).
Neither VEGF-A nor VEGF-B were able to elicit prolif-
eration in HAECs infected with Ad.AMPK-DN, whereas
either VEGF-A or VEGF-B stimulated proliferation in
Ad.control-infected HAECs (Figure 3A). In contrast,
AMPK activation in HAECs with AICAR, A769662 or
infection of HAECs with Ad.AMPK-CA all reduced
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stimulate proliferation in cells coincubated with AICAR,
yet had no effect in cells overexpressing constitutively
active AMPK (Figure 3C). Preincubation with L-NAME
had no significant effect on the inhibition of HAEC pro-
liferation in response to AICAR or infection with Ad.
AMPK-CA (Figure 3D).
AMPK does not regulate VEGF-stimulated ERK1/2 or Akt
phosphorylation
The activities of ERK and Akt have been demonstrated
to be required for endothelial cell proliferation and sur-
vival respectively [4]. We therefore determined whether
ERK or Akt phosphorylation was altered by AMPK
activity. VEGF-A caused a robust increase in ERK phos-
phorylation, whereas neither VEGF-B, nor AICAR
altered ERK phosphorylation (Figure 4A). Akt phosphor-
ylation was stimulated by VEGF-A and VEGF-B, but
unaltered by AICAR (Figure 4A). Furthermore; STO-
609 had no effect on basal or stimulated ERK or Akt
phosphorylation (Figure 4A). Co-stimulation with
VEGF-B did not alter VEGF-A-stimulated Akt, ERK or
eNOS phosphorylation, and preincubation with L-
NAME had no effect on either VEGF-A-stimulated
ERK, eNOS or Akt phosphorylation or VEGF-B-stimu-
lated Akt phosphorylation (Figure 4B)
VEGF-A stimulates HAEC migration in an AMPK-
dependent manner
VEGF-A markedly stimulated HAEC migration, whereas
VEGF-B had no significant effect on HAEC migration
(Figure 5A). Infection of HAECs with Ad.AMPK-DN
Figure 1 VEGF-B stimulates AMPK in HAECs. HAECs were incubated in the presence or absence of A-C) the indicated concentrations of VEGF-
A or VEGF-B for 5 min or D) 100 ng/ml VEGF-B for the durations indicated and lysates prepared. Lysates were subsequently subjected to A) assay
of AMPK activity or B,C,D) immunoblotting with the antibodies indicated. A) The results are expressed as the mean ± SEM% basal AMPK activity
for four independent experiments. B,D) Representative immunoblots are shown, repeated with similar results on three independent sets of
lysates. C) Quantification of immunoblots. *p < 0.05 relative to value in absence of VEGF, **p < 0.01 relative to value in absence of VEGF.
Reihill et al. Vascular Cell 2011, 3:9
http://www.vascularcell.com/content/3/1/9
Page 4 of 10prevented VEGF-A-stimulated HAEC migration, while
infection with Ad.AMPK-CA stimulated migration in
the absence or presence of VEGF-A or VEGF-B (Figure
5A). Preincubation with L-NAME attenuated VEGF-A-
stimulated HAEC migration (Figure 5B)
VEGF has no effect on fatty acid oxidation in HAECs
ACC phosphorylation by AMPK inhibits ACC activity,
reducing malonyl CoA synthesis, leading to increased
fatty acid oxidation in several tissues [12]. Indeed, incu-
bation of HUVECs with AICAR has previously been
demonstrated to stimulate fatty acid oxidation [20]. As
VEGF stimulated ACC phosphorylation (Figure 1), we
determined the effect of VEGF-A and VEGF-B on fatty
acid oxidation. Stimulation of HAECs with AICAR was
demonstrated to stimulate fatty acid oxidation 1.9 ± 0.4-
fold, yet neither VEGF-A nor VEGF-B had any effect on
HAEC fatty acid oxidation (Figure 6A).
VEGF-A stimulates HAEC fatty acid uptake in an AMPK-
dependent manner
Recent studies have reported that prolonged incubation
with VEGF-B stimulates fatty acid uptake in several
endothelial cell types [8]. We next determined whether
VEGF-A or VEGF-B stimulated fatty acid uptake in
HAECs. Incubation of confluent HAECs for 24 h with
VEGF-A stimulated the uptake of [
3H]-palmitic acid, yet
VEGF-B had no effect on the uptake of [
3H]-palmitic
acid (Figure 6B). Stimulation of fatty acid uptake by
VEGF-A was no longer apparent in HAECs infected
with Ad.AMPK-DN compared to Ad.control-infected
cells (Figure 6B). Infection with Ad.AMPK-CA stimu-
lated basal fatty acid uptake, yet incubation with VEGF-
A or VEGF-B had no further effect on fatty acid uptake
in Ad.AMPK-CA infected cells (Figure 6B). Incubation
of HAECs with L-NAME had no effect on VEGF-A-sti-
mulated fatty acid uptake, whereas although L-NAME
appeared to suppress Ad.AMPK-CA-stimulated fatty
acid uptake, this did not reach statistical significance (p
= 0.19).
Discussion
The principal findings of this study are that i) VEGF-B
stimulates AMPK activity in HAECs and ii) AMPK is
required for HAEC proliferation in response to either
VEGF-A or VEGF-B. Incubation of HAECs with VEGF-
B robustly stimulated AMPK activity, yet the extent of
activation was modest when compared with VEGF-A.
There was no additive effect of VEGF-B on VEGF-A-sti-
mulated AMPK activity. VEGF-B activates VEGF-R1,
whereas VEGF-A activates both VEGF-R1 and VEGF-
R2. These findings suggest that VEGF-R1 stimulation
leads to AMPK activation. Stimulation of AMPK by
VEGF-B was sensitive to the CaMKK inhibitor, STO-
609, as we have previously demonstrated for VEGF-A
[14], implying that VEGF-B, via VEGF-R1 stimulates an
increase in intracellular Ca
2+ required for activation of
CaMKK. One previous study using BAECs has reported
that siRNA-mediated downregulation of VEGF-R2 abro-
gated phosphorylation of AMPK and ACC in response
to VEGF, although the particular VEGF used was not
explicitly stated [16]. When these data are taken
together with those in the current study, it suggests that
stimulation of VEGF-R1 or VEGF-R2 activates AMPK
via a CaMKK-mediated mechanism in HAECs.
Angiogenesis involves endothelial cell proliferation as
well as the migration of the cells toward an angiogenic
stimulus. Although VEGF-A isaw e l l - d o c u m e n t e ds t i -
mulus for proliferation and migration [2,4-6], there are
few published studies of the effects of VEGF-B on
e n d o t h e l i a lc e l lp r o l i f e r a t i o n ,s u r v i v a lo rm i g r a t i o n .
VEGF-B has been reported to stimulate proliferation in
bovine carotid artery endothelial cells [21] and increase
survival of mouse retinal or choroidal endothelial cells
[7]. The stimulation of HAEC proliferation in response
to VEGF-B observed in the current study represents, to
the authors’ knowledge, the first demonstration that
VEGF-B stimulates proliferation in isolated human
Figure 2 VEGF-B-stimulated AMPK Thr172 phosphorylation is
inhibited by STO-609. A) HAECs were preincubated in the
presence or absence of 10 μM STO-609 for 15 min prior to
incubation with the indicated concentrations of AICAR for 45 min or
VEGF-A and VEGF-B for 5 min and lysates prepared. B) HAECs were
incubated with VEGF-A (10 ng/ml) and/or VEGF-B (100 ng/ml) for 5
min and lysates prepared. Lysates were subsequently subjected to
immunoblotting with the antibodies indicated. Representative
immunoblots are shown, repeated with similar results on three
independent sets of lysates.
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either VEGF-A or VEGF-B was abrogated by compound
C, STO-609 or infection with Ad.AMPK-DN. These
observations establish AMPK as a key regulator of cell
proliferation in response to VEGF in HAECs. Such find-
ings are consistent with previous observations demon-
strating AMPK-mediated angiogenesis in response to
both adiponectin [22] and hypoxia [15].
Despite the requirement for AMPK in VEGF-stimu-
lated endothelial cell proliferation, activation of AMPK
with AICAR, A769662 or Ad.AMPK-CA suppressed
proliferation in the absence of VEGF. This effect of
AMPK activation alone is consistent with studies in
non-endothelial cells, where AMPK activation has been
reported to cause cell cycle arrest [23-25] and to facili-
tate apoptosis [26]. We propose that although AMPK
activation is required for VEGF-stimulated proliferation,
activation of AMPK in the absence of VEGF suppresses
proliferation. In agreement with this hypothesis, VEGF
was able to stimulate proliferation in AICAR-treated
cells. In contrast, however, VEGF was unable to stimu-
late proliferation in cells infected with Ad.AMPK-CA.
As the HAECs were infected with Ad.AMPK-CA 24 h
prior to the addition of VEGF, the inability of VEGF to
Figure 3 AMPK is required for VEGF-stimulated HAEC proliferation. HAECs were incubated in the presence or absence of VEGF-A (10 ng/
ml), VEGF-B (100 ng/ml), Compound C (5 μM), STO-609 (5 μM), AICAR (2 mM), A769662 (10 μM), L-NAME (1 mM) for 24 h and proliferation
assessed. Ad.control, Ad.AMPK-DN and Ad.AMPK-CA adenoviruses were used to infect HAECs 24 h prior to the addition of VEGF. Results are
expressed as the mean ± SEM basal proliferation for three independent experiments or six independent experiments in the case of Ad.AMPK-
DN. *p < 0.05 relative to absence of VEGF, **p < 0.05 relative to absence of AICAR or A769662, ***p < 0.05 relative to Ad.control.
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to overcome sustained prior inhibition of proliferation.
VEGF stimulates a variety of signalling pathways
which are, in addition to AMPK, reported to be neces-
sary for a proliferative response. VEGF-stimulated ERK
activation has similarly been reported to be necessary
for VEGF-induced proliferation, but is not sufficient to
induce proliferation when it occurs in the absence of
VEGF [27,28]. VEGF-R2-mediated stimulation of Akt
has been reported to be required for the survival of
endothelial cells [4,29]. Activation of AMPK with
AICAR or inhibition of VEGF-stimulated AMPK activity
with STO-609 had no effect on basal or VEGF-stimu-
lated ERK or Akt phosphorylation, indicating that these
kinases are not downstream of AMPK activation. There-
fore, AMPK may act in concert with Ca
2+-independent
pathways such as ERK and Akt activation to regulate
proliferation. An alternative possible cause for the
opposing effects of AMPK activation in the presence or
absence of VEGF is that the AMPK activated by VEGF
localizes to different regions of the cell than that acti-
vated by AICAR or A769662.
NO is a key regulator of VEGF-stimulated prolifera-
tion [30], and we have previously demonstrated VEGF-
stimulated NO synthesis is, in part, downstream of
AMPK activation in HAECs [14] and therefore may be
responsible for the proliferative effects mediated by
AMPK in HAECs. Indeed, inhibition of eNOS with L-
NAME suppressed HAEC proliferation in response to
VEGF-A or VEGF-B, in agreement with previous studies
using VEGF-A [30]. Intriguingly, however, VEGF-B sti-
mulated proliferation and AMPK activity without signifi-
cantly altering phosphorylation of eNOS at Ser1177,
Figure 4 Inhibition of AMPK or eNOS has no effect on VEGF-
stimulated ERK1/2 or Akt phosphorylation. HAECs were
preincubated in the presence or absence of A) 10 μM STO-609 or B)
1 mM L-NAME for 15 min prior to incubation with the indicated
concentrations of AICAR for 45 min or VEGF-A and VEGF-B for 5 min
and lysates prepared. Lysates were subsequently subjected to
immunoblotting with the antibodies indicated. Representative
immunoblots are shown, repeated with similar results on three
independent sets of lysates.
Figure 5 AMPK is required for VEGF-A-stimulated migration.A )
HAECs were infected with Ad.control, Ad.AMPK-DN or Ad.AMPK-CA
for 24 h prior to assessment of migration in response to 10 ng/ml
VEGF-A or 100 ng/ml VEGF-B using a Boyden chamber. B) HAECs
were incubated in the presence or absence of L-NAME (1 mM) 60
min prior to incubation with VEGF-A (10 ng/ml) for 24 h and
migration assessed. The results are expressed as the mean ± SEM%
VEGF-stimulated migration for three independent experiments. *p <
0.001 relative to absence of VEGF, ** p < 0.001 relative to Ad.
control-infected cells.
Reihill et al. Vascular Cell 2011, 3:9
http://www.vascularcell.com/content/3/1/9
Page 7 of 10indicating that, in the case of VEGF-B, direct phosphor-
ylation of eNOS at Ser1177 is not required for the sti-
mulation of proliferation. Phosphorylation of eNOS at
Ser1177 is not the only mechanism by which VEGF acts
to stimulate nitric oxide synthesis, as VEGF has been
demonstrated to stimulate PLCg-mediated increases in
intracellular Ca
2+ [30,31], which act to directly stimulate
eNOS independent of phosphorylation. Indeed, it has
recently been reported that VEGF-A-stimulated phos-
phorylation of eNOS at Ser1177 was unaffected by
downregulation of AMPK by specific siRNA, yet VEGF-
stimulated angiogenesis was impaired in AMPK knock-
o u ta n i m a l s[ 3 2 ] .I tr e m a i n spossible, therefore, that
VEGF-B and VEGF-A stimulate NO synthesis indepen-
dently of either eNOS phosphorylation at Ser1177 or
AMPK and that VEGF-stimulated NO synthesis and
AMPK activation are required for HAEC stimulated
proliferation. Furthermore, L-NAME had no effect on
VEGF-stimulated ERK or Akt phosphorylation, indicat-
ing that stimulation of these pathways is independent of
VEGF-stimulated NO synthesis.
In the current study, VEGF-A, and not VEGF-B sti-
mulated migration of HAECs. Downregulation of
AMPK with adenoviruses expressing dominant negative
mutant AMPK or inhibition of eNOS with L-NAME
completely abrogated the stimulation by VEGF-A. This
is in agreement with a previous study, in which VEGF-
stimulated migration of BAECs was shown to be attenu-
ated by downregulation of AMPK or eNOS using siRNA
[16]. Similarly, infection of HUVECs with adenoviruses
expressing dominant negative mutant AMPKa2h a s
been reported to ablate VEGF-stimulated migration in
HUVECs under hypoxic conditions [15]. The lack of
effect of VEGF-B on HAEC migration may reflect the
relatively modest stimulation of AMPK (when compared
to VEGF-A or Ad.AMPK-CA). Alternatively, it is possi-
ble that VEGF-B does not stimulate AMPK activity in
the correct intracellular compartment to facilitate
migration.
For the first time, we also demonstrated that infection
of HAECs with Ad.AMPK-CA resulted in a significant
increase in cell migration in the absence of VEGF, indi-
cative of increased random cell movement (chemokin-
esis). Such an increase in chemokinesis may be a
mechanism by which endothelial cells seek nutrients
when their energy status is compromised with resultant
AMPK activation. The AMPK activators, AICAR and
phenformin have been reported to inhibit chemokinesis
in U937 promonocytic cells [33]. The different effects of
AMPK observed in the two contrasting studies are likely
to reflect the different cell types used and the potential
pleitropic effects of AICAR and phenformin.
A number of reports have demonstrated that AMPK
activation in response to AICAR, glucose deprivation
and bradykinin stimulates fatty acid oxidation in
endothelial cells [20,34]. However, in the present study
neither VEGF-A nor VEGF-B had any effect on fatty
acid oxidation in HAECs, indicating that the transient
phosphorylation of ACC in response to VEGF, unlike
the more prolonged effect of AICAR, may not be suffi-
cient to significantly increase fatty acid oxidation.
Figure 6 The effect of VEGF on fatty acid oxidation and
uptake. A) Fatty acid oxidation was assessed in HAECs incubated in
the presence or absence of the indicated concentrations of VEGF-A,
VEGF-B or AICAR for 4 h. B) HAECs were incubated in the presence
or absence of VEGF-A (25 ng/ml) or VEGF-B (250 ng/ml) for 24 h
and fatty acid uptake assessed. Ad.control, Ad.AMPK-DN and Ad.
AMPK-CA adenoviruses were used to infect HAECs 24 h prior to the
addition of VEGF. C) HAECs were incubated in the presence or
absence of VEGF-A (25 ng/ml) and L-NAME (1 mM) for 24 h and
fatty acid uptake assessed. Results are expressed as A) the mean ±
SEM basal fatty acid oxidation or B,C) the mean ± SEM basal fatty
acid uptake for 3 independent experiments performed in triplicate.
*p < 0.05 relative to Ad.control-infected HAECs. **p < 0.05 relative
to vehicle.
Reihill et al. Vascular Cell 2011, 3:9
http://www.vascularcell.com/content/3/1/9
Page 8 of 10It has recently been reported that VEGF-B signalling
upregulates fatty acid uptake in endothelial cells, a possible
consequence of increased expression of fatty acid trans-
port proteins (FATPs) [8]. Intriguingly, in confluent
HAECs, stimulation for 24 h with VEGF-A, but not
VEGF-B caused a modest, yet significant stimulation of
fatty acid transport. This effect was abrogated by infection
of HAECs with Ad.AMPK-DN and mimicked by infection
with Ad.AMPK-CA. There was no significant effect of L-
NAME on VEGF-A-stimulated fatty acid uptake. These
data indicate that, in HAECs, VEGF-A stimulates fatty
acid transport in an AMPK-dependent, NO-independent
manner. The lack of effect of VEGF-B with respect to fatty
acid transport may reflect the different source of endothe-
lial cells (HAECs) used in the current study.
Conclusions
We propose that AMPK activation is required for
endothelial cell proliferation stimulated by VEGF-A or
VEGF-B, and migration stimulated by VEGF-A, two
mechanisms that underlie the regulation of angiogenesis
by AMPK. Conversely, activation of AMPK in the
absence of VEGF, via the different signalling pathways
utilized by AICAR or A769662 suppresses proliferation
and stimulates chemokinesis. VEGF-stimulated NO
synthesis is required for proliferation and migration, yet
may not be dependent on VEGF-stimulated eNOS phos-
phorylation. Inhibition of cell proliferation by AMPK in
response to reduced energy status, in the absence of the
distinct signalling pathways induced by angiogenic fac-
tors such as VEGF, represents a facet of the classical
energy-conserving role of AMPK.
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